Clinical Trials Browser

Lymphoma, T-Cell, Peripheral × cabiralizumab × 90 days × Clear all

NCT03927105 2026-05-07

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2 Completed

4 enrolled 15 charts

Lymphoma, T-Cell, Peripheral